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Background: Primary care has an important role in cardiovascular risk management (CVRM) and a minimum size of
scale of primary care practices may be needed for efficient delivery of CVRM . We examined CVRM in patients with
coronary heart disease (CHD) in primary care and explored the impact of practice size.
Methods: In an observational study in 8 countries we sampled CHD patients in primary care practices and
collected data from electronic patient records. Practice samples were stratified according to practice size and
urbanisation; patients were selected using coded diagnoses when available. CVRM was measured on the basis of
internationally validated quality indicators. In the analyses practice size was defined in terms of number of patients
registered of visiting the practice. We performed multilevel regression analyses controlling for patient age and sex.
Results: We included 181 practices (63% of the number targeted). Two countries included a convenience sample
of practices. Data from 2960 CHD patients were available. Some countries used methods supplemental to coded
diagnoses or other inclusion methods introducing potential inclusion bias. We found substantial variation on all
CVRM indicators across practices and countries. We computed aggregated practice scores as percentage of patients
with a positive outcome. Rates of risk factor recording varied from 55% for physical activity as the mean practice
score across all practices (sd 32%) to 94% (sd 10%) for blood pressure. Rates for reaching treatment targets for
systolic blood pressure, diastolic blood pressure and LDL cholesterol were 46% (sd 21%), 86% (sd 12%) and 48% (sd
22%) respectively. Rates for providing recommended cholesterol lowering and antiplatelet drugs were around 80%,
and 70% received influenza vaccination. Practice size was not associated to indicator scores with one exception: in
Slovenia larger practices performed better. Variation was more related to differences between practices than
between countries.
Conclusions: CVRM measured by quality indicators showed wide variation within and between countries and
possibly leaves room for improvement in all countries involved. Few associations of performance scores with
practice size were found.* Correspondence: j.vanlieshout@iq.umcn.nl
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Many patients with chronic conditions are treated in pri-
mary care. This is challenging as high quality chronic
care asks for an organizational structure allowing for
population-based management. In previous research lar-
ger practice size tented to be related to higher quality of
care considering various conditions with greater diver-
sity of services [1-5]. Furthermore, larger practices
tended to show more features consistent with the deliv-
ery of chronic care [6,7]. In many countries there is a
tendency to develop larger practices [8]. Increasing size
of scale and scope may be, up to a certain point, asso-
ciated with decreasing average costs of a service as fixed
costs like participation in continued education and hir-
ing additional staff are divided by a larger number of
patients. From an educational perspective, a larger size
of scale with more patients may be associated with larger
opportunity to practice specific procedures, thus steeper
learning curves and higher quality of performance. On
the other hand, a smaller practice size may have advan-
tages in terms of more personal care and continuity [9].
Cardiovascular diseases (CVD) have major impact on
the mortality and health-related quality of life of people
in both developed and developing countries. Despite a
declining cardiovascular mortality, improvements in the
preventive, medical and surgical treatment in previous
decades, and widely accepted practice guidelines [10-12],
CVD are still one of the major causes of death and ill-
ness. Primary care can play an important role in deliver-
ing cardiovascular risk management (CVRM) to
populations, but previous research showed that not all
eligible patients receive optimal prevention of
atherosclerosis-related CVD [13,14]. Many European
countries therefore have adopted large scale programs
for improving cardiovascular risk management, includ-
ing pay-for-performance in the United Kingdom, disease
management in Germany and practice accreditation in
the Netherlands [15].
While data on CVRM are collected in a number of
countries, mostly in specialized care settings [13,14],
comparable data from primary care where many patients
are treated and counselled, was lacking. We conducted
an observational study of current CVRM in primary care
in eight European countries, focused on patients with
established coronary heart diseases (CHD) [16]. In this
paper we aimed to describe current practice across
countries and to explore associations of practice size
with CVRM measured by quality indicators.
Methods
Data were derived from the EPA Cardio study [16]. In
this cross-sectional observational study eight countries
provided data on CVRM in primary care practices: Aus-
tria, Belgium, England, France, Germany, Netherlands,Slovenia, and Switzerland. The country sample was a
convenience sample from the countries participating
within the EQuiP framework and included countries
with a strong and with a weak position of primary care
within the national health care system, and both small
and large countries[17]. Countries with a strong primary
care orientation were England, the Netherlands, and Slo-
venia; in the other countries primary care held a weaker
position within the health care organization [15,18].
Data from patient records were gathered in 2008 and
2009. Ethical approval for the study has been obtained
in each of the participating countries, according to na-
tional laws and regulations. A detailed study protocol
has been published [16].
Stratified random sampling of 36 practices per country
was planned, involving two factors: practice location (up
to versus more than 100000 inhabitants) and practice
size (up to two versus two or more full time equivalent
physicians working in the practice). The relative contri-
bution of each stratum should mirror the national situ-
ation and each country had the option to add strata in
order to better reflect the national context. Four coun-
tries used this possibility: in England large practices were
split in up to and more than five GPs; in the Netherlands
small practices were split in single handed and duo; and
in Germany and Slovenia the stratum up to 100000
inhabitants was split in up to and more than 40000 inha-
bitants. The number of practices – in relation to the pa-
tient numbers - was based on calculations of statistical
accuracy, as described in the study protocol based on
the detection of significant differences between indicator
scores between two countries[16]. It was calculated that
36 practices per country with data on 15 patients per
practice would suffice for this goal. Furthermore, earlier
experiences with international comparative data showed
that 30–40 practices can provide a reasonably good rep-
resentation of the national situation [19].
Patient population
We aimed at including 15 patients with established
CHD per practice, including patients with myocardial in-
farction, angina pectoris or coronary interventions.
Patients with diabetes were excluded because diabetes
care and care for CHD patients are largely congruent.
With diabetes patients included our results in part
would be determined by diabetes care. In each practice a
list of eligible patients was made, preferably based on
coded diagnoses in the data files of patients registered
with the practice. Then a random sample of 30 patients
was taken from this list of CHD patients anticipating a
50% response rate. As variation across countries was
anticipated related to the possibilities to generate patient
lists, as second choice, other methods were allowed, for
instance going through patient lists or simply by
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and Slovenia patient selection was exclusively based on
recorded diagnoses. Apart from coded diagnoses, in Ger-
many and Switzerland, the GP selected extra patients by
recalling CHD patients in practices with less than 30
patients with a coded diagnosis of CHD. In two coun-
tries it appeared impossible to select patients based on
coded diagnoses. In Austria, patient selection was based
on going through prescription lists. In France, primary
care physicians included eligible patients when they vis-
ited the practice. For this study we excluded practices
with data on less than 8 CHD patients.
Measures
Measures were linked to a set of rigorously developed
performance indicators for CVRM [20]. To develop
these indicators we used a RAND Modified Delphi pro-
cedure with two rounds of consensus, with 101 general
practitioners from nine countries involved in the con-
sensus process. From an original list of 650 indicators
derived from the scientific literature, we first identified
and edited 186 unique indicators. After two rounds of
consensus 17 indicators relevant for patients with estab-
lished CHD were selected; for 11 out of these 17 indica-
tors data could be collected by extraction from medical
records. These indicators comprised the registration of
risk factors (smoking status, physical activity capacity,
weight or body mass index, blood pressure, and serum
cholesterol), advice on physical activity, influenza vaccin-
ation, antiplatelet and statin drug therapy prescribed or
offered, systolic and diastolic blood pressure below
threshold (140 and 90 mmHG respectively). Though not
identified as a key-indicator we also present data on
LDL-cholesterol levels because these data are widely
seen as an important treatment goal [10-12]. All mea-
sures were systematically translated into the different
countries’ languages, with established procedures of for-
ward and backward translation and a pilot testing. The
final instrument to collect the data from the patient
records was tested and adapted in a pilot project in five
countries including two practices [21].
Analysis
We calculated descriptive figures per practice providing
data on practice size and CVRM. For each practice the
percentages of patients with a positive score on indica-
tors were assessed; patients with a missing value were
excluded for this outcome measure. We determined the
mean scores across practices per country with standard
deviations, implying that each practice had equal weight
irrespective of the number of patients included. We
tested whether the country means deviated significantly
from the grand mean, using two-sided t-tests consider-
ing Levine’s test results. As the analyses of countrydifferences are explorative a threshold value of p<0.01
was chosen to reduce the possibility of chance
capitalization.
Based on the reported practice size - patient list size
when available, otherwise yearly attending patient num-
bers - using a logistic multilevel regression analysis we
assessed the association between indicator scores and
practice size per country with two levels: a patient and a
practice level. Age and gender were independent vari-
ables in the first level (patient level). In these analyses
practice size was based on patient number as a continu-
ous factor and not on the number of GPs in the practice
what was used only for easy definition of stratification
groups.
Furthermore, we performed a three level logistic re-
gression analysis with country as a fixed factor in the
third level. For this analysis we standardized practice size
per country. With this methodology we corrected for
the differences in practices sizes between the countries
as we were not interested in country differences but in
the effect of practices size across countries. Furthermore,
this transformed patient numbers to comparable data in
all countries, even comparing countries with numbers
from patients lists and countries with numbers of
attending patients. We assessed the association between
practice size and indicator scores across all countries
and across the countries with a strong and a weak pri-
mary care system apart. Related to practice size we
hypothesized that larger practices would perform better;
for these hypothesis driven analyses we used p<0.05 as
threshold for significance.
We assessed the contribution of practices and of coun-
tries to the variance in scores on the performance indi-
cators. The Intra Class Coefficients were computed
based on the methodology described by Twisk [22].
SPSS 16 was used for descriptive analysis and t-tests,
SAS for random coefficient regression modelling.Results
In several countries it appeared impossible to include 36
practices. Finally 232 practices participated (81% of the
number aimed at). We excluded 51 practices because
they did not provide data on practice size (n=14),
included less than eight CHD patients (n=33), or both
(n=4). In this study we included 181 practices. In Austria
and Switzerland a convenience sample of practices parti-
cipated; in Belgium additional to practices from a list
four practices were included after they were personally
contacted by the researchers. All other countries worked
with national or regional practice lists. Practices in Aus-
tria, Germany, and Switzerland reported on the yearly
attending population; in the other countries practice size
was based on the number of patients listed.
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patients, on average 16.4 per practice. Overall 33% of the
patients included were female and the overall mean age
was 68.7 years (see Table 1).
Cardiovascular risk management
Regarding cardiovascular risk factor recording, the per-
centage of missing values was consistently 3 to 4%. The
mean practice score of recording physical activity cap-
acity was, on average, about 50% (see Table 2). Overall,
blood pressure recording had the highest score (94%),
followed by cholesterol levels (87%). Standard deviations
are indicative of the differences between practices.
Indicators concerning achievement of target values for
SBP, DBP and LDL, considering the most recent mea-
surements, are displayed in Table 3. We had data of
about 90% of the patients. Overall, the mean practice
score on the indicator DBP below 90 mmHg was 85%,
and on SBP and LDL cholesterol about 45%. On average
the scores on the recommended cholesterol lowering
and anti-platelet drug treatment were 80%. The practice
mean score on influenza vaccination was less than 70%.
Risk factor recording in general was below the mean
in the Netherlands; in England most factors were
recorded significantly more often. The other countries
showed less deviations from the grand mean scores (see
Table 2). Considering the outcomes advice on physical
activity, influenza vaccination, antiplatelet and statin
drug therapy, blood pressure and cholesterol levels (see
Table 3) England again scored above the mean in 4 of
the 7 outcomes. Here the Netherlands and Slovenia out-
performed on one outcome, respectively influenza vac-
cination and antiplatelet drug therapy.
Practice size
In the analyses per country practice size did not con-
sistently correlate to the outcomes (data not shown).
In Slovenia 4 of the 12 outcomes (recording of phys-
ical activity capacity and BMI or weight, advice orTable 1 Practice sample and demographic data.
Practices (n) Mean practice size (sd)
Austria 23 2878* (1369)
Belgium 18 3035 (2363)
England 32 6573 (3655)
France 9 1417 (754)
Germany 13 4423*(1608)
The Netherlands 34 3183 (1215)
Slovenia 35 2059 (804)
Switzerland 17 3449* (2537)
total 181 3538 (2582)
* Practices size provided by practices as number of yearly attending patients; in allcontraindication for physical activity, influenza vaccin-
ation) had a significant positive association with prac-
tice size; 7 outcomes were non-significant positive and
one was non-significant negative. We found one other
significant association: In England practice size and the
indicator score related to influenza vaccination were
negatively associated.
For the outcome measure recording of physical activity
capacity all countries showed a positive association,
though significant only in Slovenia.
Across all 8 countries we found no association be-
tween practice size and indicator scores. In countries
with a strong primary care system practice size was posi-
tively associated with the score on influenza vaccination
(OR 1.28, 95%CI 1.01 – 1.61) and negatively with the
LDL cholesterol level score (OR 0.86, 95%CI 0.74 –
0.99). In countries with a weak primary care system we
could not detect associations between practise size and
outcomes.
We assessed the relative contribution of practices and
countries to the variance in indicator scores, the ICC
scores (See Table 4). Of the indicator scores on SBP,
DBP and LDL about 10% of the variance could be
explained at the practice and country level together. In
all other indicators more of the variance could be
explained, about 15-30% at the practice level and up to
18% at the country level.Discussion
This is, to our knowledge, the first study on CVRM in
European primary care at a larger scale. We found that
scores on quality indicators in general vary from 45% (a
record of advice on physical activity; SBP and LDL below
treatment targets) up to about 95% (blood pressure
recording) of the maximum score, which indicates opti-
mal policy. As opposed to our expectation, we found lit-
tle evidence for better performance in large practices. In
Slovenia larger practices tended to perform better. OurPatients (n) % female Mean age (years)
293 36 71.6
232 25 66.7
479 39 68.2
133 26 67.8
248 35 70.0
495 29 69.3
805 36 68.3
275 24 68.2
2960 33 68.7
other countries as number of patients listed.
Table 2 Indicator scores: risk factor recording
Smoking
status
Physical
activity
capacity
Weight/
BMI
Blood
pressure
Serum
cholesterol
Austria Mean 100" 50.6 61.4 94.2 95.7"
SD 0 31.2 33.0 7.1 6.0
p .000 .566 .311 .957 .000
Belgium Mean 76.7 52.6 84.4" 98.0" 95.4"
SD 29.0 34.5 15.1 4.2 6.7
p .708 .805 .001 .004 .000
England Mean 94.8" 64.1 82.9" 98.3" 94.6"
SD 10.0 29.4 22.1 3.4 7.5
p .000 .121 .003 .000 .000
France Mean 79.4 46.0 90.9" 96.2 96.4"
SD 21.5 39.6 11.0 7.7 6.7
p .983 .439 .000 .555 .002
Germany Mean 92.5" 55.6 65.2 96.3 94.2
SD 9.9 41.5 33.3 7.0 8.9
p .001 .933 .662 .462 .016
Netherlands Mean 57.2# 41.7 44.6# 82.0# 67.2#
SD 28.3 27.7 27.3 15.8 19.5
p .000 .030 .000 .000 .000
Slovenia Mean 76.5 60.0 70.8 97.4 83.6
SD 26.2 29.0 25.0 67 14.4
p .580 .358 .705 .021 .253
Switzerland Mean 65.4 62.8 71.4 96.6 87.8
SD 38.1 34.8 24.4 5.9 10.8
p .162 .323 .727 .324 .830
Total Mean 79.3 54.6 68.8 94.1 86.9
SD 27.5 32.2 28.8 10.4 16.0
Mean practice scores (%) per country and across countries with standardized variation. Scores significantly deviating from the mean of all countries are marked
when p<0.01, with p values displayed.
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CVRM.
Similar to our research, the three EUROASPIRE sur-
veys provide data from international research with uni-
form data collection across countries. But in
EUROASPIRE a specialist care starting point guided
CHD patient selection [23]. Raised blood pressure,
defined as SBP≥140 mmHg and/or DBP≥90 mmHg or
in diabetics respectively ≥130 mmHg and ≥80 mmHg,
was prevalent in 58-61% of these survey samples.
Raised cholesterol was defined as ≥4.5 mmol/l and
diminished from 94.5% in EUROASPIRE I, to 76.7% in
the second survey and finally to 46.2% in the third.
Data collected in the most recent EUROASPIRE sur-
vey in 2006 and 2007 are comparable to our results.
In the Pinnacle programme, data regarding outpatients
from cardiology offices, too, show comparable results
with for instance antiplatelet and statin therapy in
84.9% and 84.3%, respectively [14]. Previous data onCVRM in primary care can be found in various na-
tional studies. In a Cochrane review the effects of
interventions on the organisation of the treatment con-
sidering ischemic heart disease patients in primary care
are studied. [24]. Data from the control groups could
be considered comparable to our audit data. Direct
comparable outcomes are statin prescription and anti-
platelet therapy. In the review 50.1 of the control
patients received statin therapy, but studies dated back
till the 1990’s. The most recent study, SPHERE, had
with 80.3% a result comparable to 82.7% in our study.
Relating to antiplatelet therapy the review result was
72.5% compared to 87.7 in our study sample. Again,
the more recent data were the best, up to 87.0 In the
SHERE study SBP was <140 mmHg in 66.2% (versus
47.5% in our data) and DBP<90 mmHg in 88.6% of
the patients (comparable to 85.5% in our data).[25] In
drug trials efficacy of statins varies from 60 to 90% in
achieving LDL < 2.5 mmol/l [26-29]. In our
Table 3 Indicator scores
Advice/
contraindication
physical activity
Influenza
vaccination
Antiplatelet
therapy if not
contra-indicated
Statin
recorded/
offered
SBP below
threshold1
DBP
below
threshold2
LDL
below
threshold3
Austria Mean 61.1 49.9 86.4 78.8 46.7 86.0 59.1
SD 30.8 29.2 25.1 22.5 20.9 9.5 22.5
p .062 .012 .739 .317 .850 .871 .022
Belgium Mean 39.3 90.7" 90.1 85.8 55.4 85.0 46.6
SD 32.1 12.2 12.3 12.2 21.3 12.6 16.3
p .317 .000 .553 .427 .065 .870 .816
England Mean 48.1 87.3" 90.8 90.2" 43.3 95.7" 65.5"
SD 30.7 14.4 10.5 10.8 14.8 5.1 15.1
p .917 .000 .171 .002 .404 .000 .000
France Mean 45.7 50.7 88.0 86.4 61.4 90.2 38.9
SD 39.0 31.9 15.3 21.4 18.3 10.7 19.6
p .876 .114 .966 .513 .029 .260 .247
Germany Mean 56.3 74.9 69.3 69.5# 52.3 81.2 37.1
SD 45.0 31.4 25.4 17.1 20.5 10.8 13.8
p .497 .520 .023 .006 .282 .204 .090
Netherlands Mean 28.8# 96.8" 82.8 77.9 28.9# 81.0 43.0
SD 22.9 5.8 18.2 15.9 15.6 12.7 20.8
p .000 .000 .129 .120 .000 .046 .261
Slovenia Mean 54.9 33.3# 92.9" 84.2 46.0 80.2 37.8
SD 29.5 32.6 8.9 13.2 18.7 12.5 20.7
p .212 .000 .010 .612 .968 .018 .016
Switzerland Mean 52.3 56.9 94.1 84.7 59.8" 87.3 41.5
SD 38.9 28.1 9.9 15.2 23.4 11.5 23.7
p .567 .159 .128 .625 .010 .570 .303
Total Mean 47.4 68.8 87.7 82.7 45.8 85.5 47.5
SD 33.0 33.5 16.9 16.3 20.9 12.1 21.8
Mean practice scores (%) per country and across countries with standardized variation. Scores significantly deviating from the mean of all countries are marked
when p<0.01, with p values displayed.
1 SBP below threshold: SBP<140 mmHg.
2 DBP below threshold: DBP<90 mmHg.
3 LDL below threshold: LDL<2.5 mmol/l.
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lower end of this range. In contrast to the optimum
situation in these drug studies physicians could include
every patient known to have a CHD, patients without
further medical attention, too. The indicator on LDL
cholesterol treatment target surprisingly was not vali-
dated in the Delphi indicator development procedure.
We can only speculate about the reasons; setting strict
norms irrespective of the patient’s age might be argued
by some or the fact that this outcome measure very
much depends on the patient in contrast to process
measures as offering a statin. In view of the strong
evidence base for the relationship between LDL choles-
terol and coronary heart disease we anyhow decided to
include the LDL cholesterol results in our study.Since most patients with increased cardiovascular risk
are treated in primary care, the findings are relevant for
improving care in the different countries despite study
limitations. They show that specific countries scored
high on some indicators and low on others. Improve-
ments in CVRM are possible in all countries. Our study
allowed to include all patients with a known diagnosis of
CHD. Inevitably, patients treated in secondary care
could be included, too. Our results give an overview of
the performance of CVRM related to all patients known
in the primary care practice.
In England high scores on performance indicators
were observed, particularly for indicators incentivized
as part of the Quality and Outcomes Framework
(QOF) [30]. Physicians in England are forced, by their
Table 4 Intra Class Coefficients
Indicator Country
level
Practice
level
Smoke status recorded 11.6 31.7
Physical activity capacity recorded 0.9 29.1
Weight or BMI recorded 7.6 24.7
Blood pressure recorded 16.4 28.4
Cholesterol recorded 17.0 19.3
Advice or contraindication
for physical activity
2.1 28.6
Influenza vaccination 18.2 17.9
Antiplatelet therapy 6.1 26.1
Statin advised or prescribed 2.5 15.2
SBP below threshold 3.4 7.9
DBP below threshold 3.8 7.4
LDL below threshold 3.6 6.5
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indicators, which might be a strong driver for change
in registration, enhancing good risk factor registration
in England. On the other hand, we found relatively
low performance scores for some indicators of CVRM,
especially risk factor recording, in the Netherlands.
The only indicator related to a financial incentive (in-
fluenza vaccination) and supported by a national
organizational programme had very high scores in this
country (in 2009 a fee of 9.88 euro was provided for
every vaccinated patient). The system parameter incen-
tives on a national level and as such as a country
characteristic may have an important influence relative
to practice size as a practice characteristic.
The DBP indicator scores were much higher than
scores for SBP, though the importance of the latter is
stressed by its role in risk classification schemes. Advice
on physical activity had low scores, too, although it
remains uncertain whether such advice had been pro-
vided but not recorded.
Differences between countries may be partly explained
by differences in the quality of recording as stated above.
Medication and blood pressure or cholesterol levels are
probably well recorded, but this is less the case for
smoking status or exercise advice. It might be argued
that recorded care does not mirror care provided. But in
chronic care recording is thought to be essential. Risk
factor recording is a prerequisite to select patients for
treatment and chronic care means collaboration between
various health care professionals, who will need to rely
on the data in the patient records [31].
In our study practice size seems to have little relation
to performance as measured by quality indicators.
Though in previous research on practice size no consist-
ent results were found, in general larger practices tend
to show better performances and provide more extensiveservices, for instance more preventive activities [1-5]. All
these studies were based on national data. We took into
account the fact that we had practices from eight coun-
tries by entering country as a level in our multilevel ana-
lysis. This procedure effected chance on significant
findings. Taking into account the strength of the primary
care did not provide relevant findings.
A larger practice offers opportunities to develop skills
by experience and gives managerial advantages, espe-
cially when specialized staff is required. Structured care
will be more cost effective with larger patient groups
included in a program. On the other hand, there seems
to be a trade of between high quality clinical care and
interpersonal care, and access might be better in smaller
practices [2,9]. In our sample across countries small
practices were able to deliver a performance on cardio-
vascular risk management as good as larger practices.
Only in Slovenia larger practices showed a tendency
towards better performance in general. We can only
hypothize on this finding. It may be the resultant of re-
cent implementation strategies with first effects in larger
settings. This would be in line with the general concept
of larger practices being in a good position for providing
structured care to larger groups of patients.
The proportion of variance explained at the practice
level was larger than that related to the country level, in-
dicating that the practice has more influence on that
variation than the country. This could stimulate prac-
tices to invest in quality improvement in their practices
as there is little argument that much is determined at a
higher level out of their reach. A remarkable small part
of the variation in outcomes is explained at both the
practice and the country level considering the blood
pressure and cholesterol levels. These biological out-
comes will be determined at the patient level to a greater
extend.
Strengths and limitations of the study
Within the context of our international survey we had
to face inclusion bias both at the practice level and at
the patient level as a result of differences in the
organization of the health care system within the various
countries at different levels. Practice selection was ran-
dom in most countries but a convenience sample in two
countries (Austria and Switzerland). The procedure for
sampling patients, too, showed some variation. In Bel-
gium, England, the Netherlands and Slovenia patient se-
lection was exclusively based on recorded diagnoses,
enabling inclusion of patients registered but not con-
trolled in primary care or not at all. Less strict methods
were used in the other countries (remembering patients,
prescription lists, attending patients) providing patient
inclusion bias. Patients on a prescription list by defin-
ition have some drug treatment and frequent attenders
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Our practice sample appeared the best feasible given the
limitations of our international survey. The sample size
of 181 practices forms a limitation to detect small effects
of practice size on outcomes, among other due to clus-
tering within countries and differences of possible effects
between countries.
Data on practice size were not directly comparable
between countries because of the differences in health
care systems. In some but not all countries patients
are listed with one GP or practice. Countries without
these clear patients’ lists had to report on numbers of
attenders as a measure for practices size. By standard-
izing practice size data per country we solved this po-
tential problem.
We included patients with CHD to have a patient
group more homogeneous than the group of CVD
patients in general. This did not completely prevent het-
erogeneity within our study population. The CHD group
comprised on the one hand patients who had a myocar-
dial infarction or vascular surgery and have been treated
in secondary care and on the other hand patients with
stable angina pectoris who might have been treated in
primary care exclusively.
Conclusions
The variation between practices within each country is
unwanted and proves potential for improvement. The
presence of highly performing practices within each
country proves that in each national context good
CVRM is possible. Differences found between countries
and especially best practices can form lessons for all
countries. For instance the Quality and Outcomes
Framework from the UK can be an example to other
countries but focus may differ according to the national
situation as the position of primary care within the lar-
ger context of the health care system.
In contrast to most previous research our analysis did
not indicate significant influence of practice size on the
quality indicator scores. In various studies larger prac-
tices tend to perform better, supporting the development
of practice collaboration with consequently larger groups
of CHD patients to organize care. This may enhance ex-
pertise and logistics. We could not confirm this ten-
dency. Here, further research is needed.
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